MMC in Trabeculectomy
Phase 3Small molecule
MMC in Trabeculectomy is one of 27 small molecule programs targeting Glaucoma. It is currently in Phase 3.
1
Indications
2
Total Trials
0
Active Trials
26
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
182 competitors in Glaucoma
#DrugCompanyPhaseTrials
1Lucentis
RochePhase 3
Namenda
AbbViePhase 3
Avastin
BBio-Thera Solutions
Phase 3
Viagra
VViatris Specialty LLC
Phase 3
Betoptic
SanofiPhase 3
Tocopherol
MM.D. Anderson Cancer Center
Phase 3
Zioptan
MMeitheal
Phase 3
TFC-003
KKukje Pharma
Phase 3
MMC in Trabeculectomy
PPro Top & Mediking Company Limited
Phase 3
Alphagan
AbbViePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MMC in Trabeculectomy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details